Background: Ependymoma is a rare type of glioma, representing 5% of all CNS malignancies.
Ependymomas are CNS neuroepithelial tumors that are thought to arise from ependymal cells in supratentorial, infratentorial, and spinal locations. They are rare, comprising approximately 5% of all CNS malignancies. 1 Ependymoma (WHO grade II) and anaplastic ependymoma (WHO grade III) are characterized by local recurrence and distant metastasis through CSF pathways despite maximal resection and regional radiation therapy (RT) . In contrast to other glioma subtypes such as glioblastoma, the low incidence limits the capability to conduct large prospective clinical trials, and management is based mainly on small case studies. Retrospective series in recurrent disease suggest that approximately one-third of patients respond to platinum-based chemotherapy regimens, and nitrosoureas also may benefit individual patients, 2 but most patients have stable disease as best response and true regression is uncommon. Consequently, there is no standard chemotherapy regimen.
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF), preventing the binding of VEGF to its receptors on the surface of endothelial cells. Bevacizumab is active against colorectal, non-small cell lung, and breast cancers, and has demonstrated promising activity in other malignant gliomas, such as glioblastoma, for which it received accelerated approval from the Food and Drug Administration. 3, 4 In addition, ependymomas express VEGF. 5 Therefore, we report our experience treating 8 patients with recurrent ependymoma or anaplastic ependymoma using bevacizumab alone or in combination with chemotherapy.
METHODS We retrospectively identified adults treated for recurrent ependymoma or anaplastic ependymoma with bevacizumab-containing chemotherapy regimens since 2006 (when bevacizumab became widely used for gliomas). We sought to determine radiographic response (Macdonald criteria) 6 and estimated median time to progression (TTP) and overall survival (OS) by the Kaplan-Meier method (level of evidence class III, level U) from the beginning of bevacizumab. Data were updated as of April 16, 2009.
Standard protocol approvals, registrations, and patient consents. This study was approved by the Memorial Sloan-
Kettering Cancer Center; the University of California, Los Angeles; and the University of Lausanne Institutional Review Boards with a waiver of consent. RESULTS There were 8 patients, 4 of whom were women, with a median age of 40 years (range, 20 -65). Five patients had supratentorial disease, 2 infratentorial disease, and 1 both. Prior treatment included surgery and RT in all, temozolomide in 5, and carboplatin in 4. Bevacizumab (5-15 mg/kg every 2-3 weeks) was administered as monotherapy to 2 patients and combined with cytotoxic agents in 6: irinotecan (3), carboplatin (2), or temozolomide (1). All patients were evaluated for best radiographic response, which was partial in 6 (figure), stable (for Ͼ8 months) in 1, and progressive disease in 1 (table), giving a 75% radiographic response rate. Among 4 patients with carboplatin-resistant disease, 3 responded (table) . Median TTP was 6.4 months (95% confidence interval [CI] 1.4 -7.4) and median OS was 9.4 months (95% CI 7.0 -not reached). Median follow-up was 5.2 months among 5 surviving patients (63%). Clinical improvement was also observed in 2 of the 6 patients who were both symptomatic and achieved either radiographic response or stabilization. In the single patient taking corticosteroids, bevacizumab treatment enabled discontinuation. DISCUSSION Ependymoma is a rare CNS tumor for which there is no standard chemotherapy and few published reports of active agents. A retrospective study of various chemotherapy regimens in 28 adults with recurrent cerebral ependymoma (17 WHO grade II; 11 WHO grade III) identified an overall response rate of 21%, median TTP of 9.9 months (95% CI, 7.5-21.7), and median OS of 40.7 months (95% CI, 16 -not reached). 2 Platinum-containing regimens appeared to be the most beneficial, but only a minority of patients (31%) responded. 2 A phase II study of temozolomide, the most commonly prescribed chemotherapy for other glioma subtypes, 7 yielded no responses among 14 children and adolescents with recurrent ependymoma. 8 A preliminary report of a prospective study suggests some adults benefit from temozolomide. 9 Immunohistochemical and in situ hybridization studies show significant VEGF expression by ependymomas. 5 Serial measurement of serum VEGF in pediatric patients treated with RT for ependymoma showed a significant decline in the 12 months following treatment. 10 Therefore, VEGF inhibition may be an effective strategy in the treatment of ependymoma. We observed responses in 6 of 8 patients and clinical benefit (response or stabilization) in 7 treated with bevacizumab-containing regimens. Moreover, our patients represent a subgroup with a particularly poor prognosis. All had recurrent disease after surgical resection and radiation therapy, and 6 had also received chemotherapy for prior recurrences, including a platin in 4. Nevertheless, we found that 75% responded to bevacizumabcontaining regimens, and 88% achieved at least temporary disease control.
Radiographic assessment of glioma response to antiangiogenic therapy is problematic. Traditional criteria depend upon serial measurement of the crosssectional area or volume of contrast-enhancing tumor. 6 Like corticosteroids, VEGF inhibitors such as bevacizumab decrease vascular permeability, reducing both cerebral edema and contrast enhancement. Therefore, it is possible that the apparent responses we observed reflect restoration of a disrupted blood-brain barrier. However, leptomeningeal disease, in which there is no tumor mass disrupting the blood-brain barrier, also responded to bevacizumab (figure e-1 on the Neurology ® Web site at www.neurology.org). In addition, the 95% CIs for our median TTP and OS overlap with those reported by others for platinum-based therapy (5.2 months-not reached for TTP and 21 months-not reached for OS), 2 suggesting that bevacizumabcontaining regimens are not inferior. Furthermore, we observed responses or stabilization in 75% (3 of 4) of platinum-resistant tumors and 80% (4 of 5) of temozolomide-resistant tumors. Finally, radiographic response or stabilization was associated with clinical improvement or reduced corticosteroid dependence in 3 patients.
Six of our patients (table) with stable disease or partial response received concurrent carboplatin, temozolomide, or irinotecan, making it difficult to attribute disease stability control to bevacizumab alone. In addition, prior therapy in all of our patients was heterogeneous; therefore, we cannot exclude the possibility that patients treated earlier in the course of their disease might have a tumor that is more sensitive to therapy in general. Nonetheless, in some patients, use of bevacizumab-containing regimens appears to delay tumor progression and may be reasonable depending on potential cost and risk tolerance. The true efficacy of bevacizumab in recurrent ependymoma must be determined in a prospective clinical trial.
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